1697 related articles for article (PubMed ID: 18816795)
21. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
23. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
[TBL] [Abstract][Full Text] [Related]
24. Exercise exerts neuroprotective effects on Parkinson's disease model of rats.
Tajiri N; Yasuhara T; Shingo T; Kondo A; Yuan W; Kadota T; Wang F; Baba T; Tayra JT; Morimoto T; Jing M; Kikuchi Y; Kuramoto S; Agari T; Miyoshi Y; Fujino H; Obata F; Takeda I; Furuta T; Date I
Brain Res; 2010 Jan; 1310():200-7. PubMed ID: 19900418
[TBL] [Abstract][Full Text] [Related]
25. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
26. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
27. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion.
Zuch CL; David D; Ujhelyi L; Hudson JL; Gerhardt GA; Kaplan PL; Bickford PC
Brain Res; 2004 Jun; 1010(1-2):10-6. PubMed ID: 15126112
[TBL] [Abstract][Full Text] [Related]
29. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
[TBL] [Abstract][Full Text] [Related]
30. Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats.
Borlongan CV; Zhou FC; Hayashi T; Su TP; Hoffer BJ; Wang Y
Neurobiol Dis; 2001 Aug; 8(4):636-46. PubMed ID: 11493028
[TBL] [Abstract][Full Text] [Related]
31. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
33. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.
Opacka-Juffry J; Ashworth S; Hume SP; Martin D; Brooks DJ; Blunt SB
Neuroreport; 1995 Dec; 7(1):348-52. PubMed ID: 8742486
[TBL] [Abstract][Full Text] [Related]
34. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease.
Zhu G; Wang X; Chen Y; Yang S; Cheng H; Wang N; Li Q
Planta Med; 2010 Nov; 76(16):1820-6. PubMed ID: 20509103
[TBL] [Abstract][Full Text] [Related]
35. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
Tsuboi K; Shults CW
Exp Neurol; 2002 Jan; 173(1):95-104. PubMed ID: 11771942
[TBL] [Abstract][Full Text] [Related]
36. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
[TBL] [Abstract][Full Text] [Related]
37. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
38. Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.
Kim YK; Lim HH; Song YK; Lee HH; Lim S; Han SM; Kim CJ
Neurosci Lett; 2005 Aug 12-19; 384(1-2):133-8. PubMed ID: 15893426
[TBL] [Abstract][Full Text] [Related]
39. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons.
Piltonen M; Bespalov MM; Ervasti D; Matilainen T; Sidorova YA; Rauvala H; Saarma M; Männistö PT
Exp Neurol; 2009 Oct; 219(2):499-506. PubMed ID: 19615368
[TBL] [Abstract][Full Text] [Related]
40. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
